J
Julie Pildal
Researcher at Cochrane Collaboration
Publications - 14
Citations - 2265
Julie Pildal is an academic researcher from Cochrane Collaboration. The author has contributed to research in topics: Randomized controlled trial & Blinding. The author has an hindex of 11, co-authored 14 publications receiving 2085 citations. Previous affiliations of Julie Pildal include Copenhagen University Hospital & Steno Diabetes Center.
Papers
More filters
Journal ArticleDOI
Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials.
Jelena Savović,Hayley E Jones,Douglas G. Altman,Ross J Harris,Peter Jüni,Julie Pildal,Bodil Als-Nielsen,Ethan M Balk,Christian Gluud,Lise Lotte Gluud,John P. A. Ioannidis,Kenneth F. Schulz,R Beynon,Nicky J Welton,Lesley Wood,David Moher,Jonathan J Deeks,Jonathan A C Sterne +17 more
TL;DR: For each characteristic, average bias and increases in between-trial heterogeneity were driven primarily by trials with subjective outcomes, with little evidence of bias in trials with objective and mortality outcomes.
Journal ArticleDOI
Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies
Jelena Savović,Hayley E Jones,Douglas G. Altman,RJ Harris,P Jűni,Julie Pildal,Bodil Als-Nielsen,Ethan M Balk,Christian Gluud,Lise Lotte Gluud,Jpa Ioannidis,Kenneth F. Schulz,R Beynon,Nicky J Welton,Lesley Wood,David Moher,Jonathan J Deeks,Jac Sterne +17 more
TL;DR: Bias associated with specific reported study design characteristics leads to exaggeration of beneficial intervention effect estimates and increases in between-trial heterogeneity, and assessments of the risk of bias in RCTs should account for these findings.
Journal ArticleDOI
Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials
Julie Pildal,Asbjørn Hróbjartsson,Karsten Juhl Jørgensen,Jørgen Hilden,Douglas G. Altman,Peter C Gøtzsche +5 more
TL;DR: Two-thirds of conclusions in favour of one of the interventions were no longer supported if only trials with adequate allocation concealment were included, and the loss of support mainly reflected loss of power and a shift in the point estimate towards a less beneficial effect.
Journal ArticleDOI
Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study
Julie Pildal,An-Wen Chan,Asbjørn Hróbjartsson,Elisabeth Forfang,Douglas G. Altman,Peter C Gøtzsche +5 more
TL;DR: Most randomised clinical trials have unclear allocation concealment on the basis of the trial publication alone, and most of these trials also have unclear allocations concealment according to their protocol.
Journal ArticleDOI
Polyclonal Immunoglobulin for Treatment of Bacterial Sepsis: A Systematic Review
Julie Pildal,Peter C Gøtzsche +1 more
TL;DR: Because high-quality trials failed to demonstrate a reduction in mortality, polyclonal immunoglobulin should not be used for treatment of sepsis except in randomized clinical trials.